Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Escalating Starting Dose of Lenalidomide and Concomitant Evaluation of Safety and Efficacy

NCT01703364 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.

NCT NCT01703364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01703364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Escalating Starting Dose of Lenalidomide and Concomitant Evaluation of Safety and Efficacy
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2012
Completion date
October 31, 2015
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll